INSM Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -225.53% compared to Insmed's net margin of -18.6%. Insmed's return on equity of -41989.34% beat Baxter International's return on equity of -8.24%.

Insmed has a consensus price target of $95.66, signalling upside risk potential of 25%. On the other hand Baxter International has an analysts' consensus of $40.04 which suggests that it could grow by 15.76%. Given that Insmed has higher upside potential than Baxter International, analysts believe Insmed is more attractive than Baxter International.

Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.66% to investors and pays a quarterly dividend of $0.17 per share. Insmed pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are smaller than Baxter International quarterly revenues of $2.8B. Insmed's net income of -$235.5M is higher than Baxter International's net income of -$512M. Notably, Insmed's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 34.51x versus 1.38x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -225.53% compared to Insmed's net margin of 16.72%. Insmed's return on equity of -41989.34% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Insmed has a consensus price target of $95.66, signalling upside risk potential of 25%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.68 which suggests that it could grow by 37.78%. Given that Biomarin Pharmaceutical has higher upside potential than Insmed, analysts believe Biomarin Pharmaceutical is more attractive than Insmed.

Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Insmed's net income of -$235.5M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Insmed's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 31.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 34.51x versus 4.83x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -225.53% compared to Insmed's net margin of 9.85%. Insmed's return on equity of -41989.34% beat Amicus Therapeutics's return on equity of -35.23%.

Insmed has a consensus price target of $95.66, signalling upside risk potential of 25%. On the other hand Amicus Therapeutics has an analysts' consensus of $16.73 which suggests that it could grow by 87.95%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are smaller than Amicus Therapeutics quarterly revenues of $149.7M. Insmed's net income of -$235.5M is lower than Amicus Therapeutics's net income of $14.7M. Notably, Insmed's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 34.51x versus 5.13x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -225.53% compared to Insmed's net margin of -1816.75%. Insmed's return on equity of -41989.34% beat Ocugen's return on equity of -171.04%.

Insmed has a consensus price target of $95.66, signalling upside risk potential of 25%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1156.28%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

Insmed has a beta of 1.280, which suggesting that the stock is 27.99% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are larger than Ocugen quarterly revenues of $764K. Insmed's net income of -$235.5M is lower than Ocugen's net income of -$13.9M. Notably, Insmed's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 34.51x versus 35.90x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.